

**Oncoinvent ASA: Updated information regarding the contemplated Rights Issue and Merger**

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

Oslo, 17 September 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the "Company") and Oncoinvent ASA ("Oncoinvent") regarding the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS through a statutory triangular merger (the "Merger"). Reference is also made to the stock exchange announcement made by the Company on 30 June 2025 regarding a fully underwritten rights issue (the "Rights Issue") with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the Merger (the "Rights Issue Announcement").

As mentioned in the Rights Issue Announcement, the Company will prepare and publish an EEA prospectus for, inter alia, the offering and listing of the shares to be issued in the Rights Issue (the "Offer Shares") and for the listing of the consideration shares to be issued in the Merger (the "Merger Shares"). The prospectus will include the full terms and conditions of the Rights Issue and will be subject to approval by the Norwegian Financial Supervisory Authority prior to publication (the "Prospectus"). Due to delays in the Prospectus work stream, the key dates previously announced by the Company and Oncoinvent in connection with the Rights Issue have changed.

The first draft of the Prospectus has been submitted to the Norwegian Financial Supervisory Authority. It is expected that the Prospectus will be approved on or about 28 October 2025. Furthermore, the Company and Oncoinvent expect that the Merger will be completed on or about 29 October 2025, with the first day of trading in the shares of the combined Company expected on or about 30 October 2025. Euronext Oslo Børs has approved that conditions for the continued listing of the Company's shares on Euronext Oslo Børs after completion of the Merger are met. The subscription period for the Rights Issue is expected to commence on or about 14 November 2025 at 09:00 hours CET and expire at 16:30 hours CET on 28 November 2025. Delivery of the Offer Shares is expected to take place on or about 8 December 2025, through the facilities of the Norwegian Central Securities Depository.

For further information regarding the Rights Issue, reference is made to the Rights Issue Announcement. For further information regarding the Merger and the complete terms and conditions for the Merger, reference is made to the merger plan with appendices available on [www.bergenbio.no](http://www.bergenbio.no).

**For further information, please contact:**

Øystein Soug, CEO, Oncoinvent ASA, [soug@oncoinvent.com](mailto:soug@oncoinvent.com)

Tore Kvam, CFO, Oncoinvent ASA, [kvam@oncoinvent.com](mailto:kvam@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.